100 More Jobs Cut At Infinity After AbbVie Inevitably Ends Partnership
Executive Summary
AbbVie unsurprisingly walked away from its partnership with Infinity after disappointing Phase II results for the PI3K inhibitor duvelisib. Another 100 Infinity employees will lose their jobs as the company conserves its cash and amends its clinical trial plan.
You may also be interested in...
Verastem’s Copiktra Gets Early Approval To Challenge Zydelig, Venclexta In Third-Line CLL
Copiktra (duvelisib) becomes the first dual inhibitor of PI3K delta and gamma to hit the market, placing it in competition with Gilead’s Zydelig and AbbVie’s Venclexta.
Verastem Sees Phase III Success With PIK3 Inhibitor Dropped By AbbVie
Duvelisib, licensed from Infinity in 2016, reduces risk of disease progression or death compared to Arzerra in a Phase III study in refractory CLL/SLL. Verastem hopes to file an NDA during the first half of 2018.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.